24 Corporate Court
Guelph, ON N1G 5G5
Canada
844-730-9822
https://www.zentek.com
Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 29
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Gregory Fenton C.F.A. | CEO & Director | 236,53k | N/D | N/D |
Ms. Wendy Ford CA, CPA | Chief Financial Officer | 182,33k | N/D | N/D |
Dr. Francis Dube B.Sc. | COO & Director | 218,34k | N/D | N/D |
Dr. Colin van der Kuur B.Sc., DMIN | Chief Science Officer | 54,51k | N/D | N/D |
Mr. Ryan Shacklock | Senior Vice President of Strategy & Business Development | N/D | N/D | N/D |
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops graphene oxide synthesis and graphene synthesis. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Guelph, Canada.
L'ISS Governance QualityScore di Zentek Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.